AnaptysBio (NASDAQ:ANAB) Stock Price Up 4.4% – What’s Next?

AnaptysBio, Inc. (NASDAQ:ANAB)’s share price rose 4.4% on Thursday . The company traded as high as $17.29 and last traded at $17.17. Approximately 85,418 shares traded hands during trading, a decline of 84% from the average daily volume of 533,342 shares. The stock had previously closed at $16.44.

Analysts Set New Price Targets

ANAB has been the subject of a number of analyst reports. HC Wainwright restated a “neutral” rating and set a $22.00 target price on shares of AnaptysBio in a report on Tuesday, March 4th. JPMorgan Chase & Co. upped their target price on AnaptysBio from $36.00 to $42.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Wedbush restated an “outperform” rating and set a $40.00 target price on shares of AnaptysBio in a report on Wednesday, February 12th. Truist Financial lowered their target price on AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a report on Wednesday, December 18th. Finally, Wells Fargo & Company increased their price objective on AnaptysBio from $40.00 to $51.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $35.11.

AnaptysBio Trading Down 2.8 %

The stock has a market capitalization of $523.79 million, a price-to-earnings ratio of -2.81 and a beta of 0.02. The stock has a 50-day moving average price of $16.80 and a 200 day moving average price of $22.67.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.61) by $0.89. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The business had revenue of $43.11 million for the quarter, compared to analyst estimates of $10.17 million. Equities research analysts anticipate that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Ecor1 Capital, Llc bought 6,646 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was purchased at an average price of $12.95 per share, for a total transaction of $86,065.70. Following the completion of the purchase, the director now owns 7,880,094 shares in the company, valued at approximately $102,047,217.30. This trade represents a 0.08 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 33.70% of the company’s stock.

Hedge Funds Weigh In On AnaptysBio

A number of institutional investors and hedge funds have recently modified their holdings of ANAB. Tower Research Capital LLC TRC lifted its position in AnaptysBio by 131.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 1,531 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in AnaptysBio during the fourth quarter worth about $40,000. AlphaQuest LLC raised its holdings in AnaptysBio by 1,891.5% during the fourth quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 4,237 shares in the last quarter. Virtus ETF Advisers LLC raised its holdings in AnaptysBio by 24.7% during the fourth quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 936 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its holdings in AnaptysBio by 1,585.8% during the fourth quarter. Russell Investments Group Ltd. now owns 5,698 shares of the biotechnology company’s stock worth $75,000 after purchasing an additional 5,360 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.